Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 [Pharmacology(medical)]
Submission to first decision: 10 days

Cancer Drug Resistance

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
Marking a 13% rise, CDR continues to lead the field of cancer drug resistance.
This marks a notable 25.8% increase from last year’s score of 6.6, underscoring the CDR’s rising academic impact and global recognition.
In honor of National Cancer Survivors Month 2025, Cancer Drug Resistance (CDR) is offering a limited-time APC discount to support researchers in the vital field of cancer drug resistance.
We are thrilled to announce that Prof. Baiyong Shen, a globally recognized leader in pancreatic cancer research and Vice President of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, has officially joined Cancer Drug Resistance as an Associate Editor.
The webinar is scheduled for 7th May as an extension of the special issue.
We warmly welcome your participation and contributions.

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Coming soon.

Articles Collection
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/